Roth Capital maintained a Buy rating on Can-Fite BioPharma (NYSE: CANF) and raised its price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE